Daniel G. Welch

Mr. Welch has spent his career of 40 years in the business of developing medicines. From January 2015 to February 2018, he was an Executive Partner at Sofinnova Investments, a leading Bay Area biotech venture capital firm. Prior to joining Sofinnova Investments, he was Chairman, President and CEO of InterMune until its acquisition by Roche in October of 2014. Before InterMune, he was Chairman and CEO of Triangle Pharmaceuticals, which was acquired by Gilead in 2003. Prior to Triangle, he was President of Biopharmaceuticals at Elan Corporation where he was responsible for its worldwide pharmaceutical operations, R&D and diagnostics businesses. From 1987 to 2000, he served in various senior management roles at Sanofi, including General Manager, Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business.

Mr. Welch currently serves as Chairman of the Board of Ultragenyx Pharmaceuticals, Executive Chairman of Levo Therapeutics, Executive Chairman of InCarda, and Director of Seattle Genetics and Intercept Pharmaceuticals. He served as Chairman of the Board of AveXis Inc. until it was acquired by Novartis Pharmaceuticals in 2018, and as a Director at Hyperion Therapeutics until it was acquired by Horizon Pharma in 2015. Mr. Welch earned a B.A. from the University of Miami and an M.B.A. from the University of North Carolina.